Anvisa has issued an alert about the risk of pancreatitis linked to the use of weight loss pens, following reports of six deaths associated with GLP-1 receptor antagonists.
The Brazilian Health Regulatory Agency, Anvisa, has recently issued a warning regarding the use of weight loss pens, particularly those containing GLP-1 receptor antagonists, used primarily for diabetes treatment. This alert comes after the agency reported six fatalities connected to these medications, which have gained popularity for their weight loss benefits. Since 2020, there have been 145 suspected adverse events related to these drugs, raising significant concerns about their safety.
